Oncopeptides

Oncopeptides develops the candidate drug melflufen to improve the treatment of multiple myeloma, an incurable form of blood cancer that affects more than 100,000 people in the West each year. Melflufen has a unique mode of action and is demonstrating a high clinical anti-cancer effect and favorable side effect profile in an ongoing trial. Clinical development activities are ongoing to show its efficacy in comparison with existing treatment options. Melflufen has potential to improve the medical treatment of these extremely ill patients.

Melflufen has been granted orphan drug status in both the US and Europe. Preparations for pivotal trials in multiple myeloma are currently ongoing. Oncopeptides also intends to initiate phase I/II trials for additional cancer indications.

Oncopeptides at a glance

What they do: Preparing pivotal programs for the candidate drug melflufen – a new targeted treatment of multiple myeloma
Founded in: 2000
Headquarters: Stockholm, Sweden
www.oncopeptides.se

By continuing to interact with the site, you agree to the use of cookies. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close